Skip to content
value.today
Opko Health, Inc. logo

Opko Health, Inc.

Formerly eXegenics, Inc.

Total raised
$31 M
1 round on record
Latest round
$31 M
May 2009
First round on record
May 2009
Today
Went public
See the company page

Opko Health, Inc. is listed today as OPKO Health, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Opko Health, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2013$175 MPrivate placement after listing$50 to $250 million

Opko Health, Inc.: Private sale, Jan 2013

Investors in this round

105 investors had bought by the notice of Feb 15, 2013: 105 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$175 M of $175 M offered
Smallest investment taken
$1,000
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
$4,500,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jane H. Hsiao · Executive Officer, Director · Vice Chairman of the Board and Chief Technical Officer
  • Juan F. Rodriguez · Executive Officer · Senior Vice President and Chief Financial Officer
  • Phillip Frost · Executive Officer, Director · Chairman of the Board and Chief Executive Officer
  • Steven D. Rubin · Executive Officer, Director · Executive Vice President-Administration
  • Alice Lin-Tsing C. Yu · Director
  • Dmitry A. Kolosov · Director
  • John A. Paganelli · Director
  • Richard A. Lerner · Director
  • Richard C. Pfenniger, Jr. · Director
  • Robert A. Baron · Director
  • Thomas E. Beier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies & Company, Inc. (CRD 2347) · New York, New YorkSold in CA, CO, CT, FL, IA, IL, MA, MI, MN, NC, NJ, NV, NY, OH, PA, RI, TX, WI
  • Ladenburg Thalmann & Co. (CRD 505) · Miami, FloridaSold in FL

Remarks in the notice

  • On fees: “Total compensation was $4,500,000 and this fee was split up so that 85% of the fee ($3,825,000) was paid to Jefferies and 15% of the fee ($675,000) was paid to Ladenburg.”

Signed by Steven D. Rubin, Executive Vice President-Administration. Newest notice filed Feb 15, 2013. Read the notice at the SEC.

equity, debtSEC
May 2009$31 MNo. 1$10 to $50 million

Opko Health, Inc.: Raise no. 1, May 2009

Investors in this round

7 investors had bought by the notice of Jun 3, 2009: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jane H. Hsiao · Executive Officer, Director
  • Naveed K Shams · Executive Officer
  • Phillip Frost · Executive Officer, Director
  • Rao Uppaluri · Executive Officer
  • Steven D. Rubin · Executive Officer, Director
  • Alice Lin-Tsing Yu · Director
  • John A. Paganelli · Director
  • Pascal J. Goldschmidt · Director
  • Richard A. Lerner · Director
  • Richard C. Pfenniger, Jr. · Director
  • Robert A. Baron · Director
  • Thomas E. Beier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kate Inman, Deputy General Counsel. Newest notice filed Jun 3, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company OPKO Health, Inc., its revenue in fiscal 2025 came from these product and service lines: Transfer of Intellectual Property and Other $79.70 million (13%), Rayaldee $59.39 million (10%).

    Annual report (SEC XBRL) · Dec 2025

  • Opko Health, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Feb 2013).

    SEC Form D (revenue range) · Feb 2013

  • Revenue range over time, as stated in its notices: revenue between $5 million and $25 million in 2009; revenue between $25 million and $100 million in 2013.

    SEC Form D (revenue range) · Feb 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2013

Products and services#

No products or services of Opko Health, Inc. are on record.

Investors#

No investor of Opko Health, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding OPKO Health, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Opko Health, Inc.
NameRoleNamed in
Jane H. HsiaoVice Chairman of the Board and Chief Technical OfficerFeb 2013
Juan F. RodriguezSenior Vice President and Chief Financial OfficerFeb 2013
Phillip FrostChairman of the Board and Chief Executive OfficerFeb 2013
Steven D. RubinExecutive Vice President-AdministrationFeb 2013
Naveed K ShamsExecutive officerJun 2009
Rao UppaluriExecutive officerJun 2009
Alice Lin-Tsing C. YuDirectorFeb 2013
Dmitry A. KolosovDirectorFeb 2013
Jane H. HsiaoVice Chairman of the Board and Chief Technical OfficerFeb 2013
John A. PaganelliDirectorFeb 2013
Phillip FrostChairman of the Board and Chief Executive OfficerFeb 2013
Richard A. LernerDirectorFeb 2013
Richard C. Pfenniger, Jr.DirectorFeb 2013
Robert A. BaronDirectorFeb 2013
Steven D. RubinExecutive Vice President-AdministrationFeb 2013
Thomas E. BeierDirectorFeb 2013
Alice Lin-Tsing YuDirectorJun 2009
Pascal J. GoldschmidtDirectorJun 2009

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.